MTHFR 677TT genotype and disease risk: Is there a modulating role for B-vitamins'

Proceedings of the Nutrition Society

Volumn 73, Issue 1, 2014, Pages 47-56

  Reilly, R ^a   McNulty, H ^a   Pentieva, K ^a   Strain, J J ^a   Ward, M ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

CVD; Folate; Hypertension; MTHFR 677C T polymorphism; Neural tube defects; Riboflavin

Indexed keywords

BLOOD PRESSURE; FEMALE; FOLIC ACID; GENOTYPE; HUMANS; HYPERTENSION; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NEURAL TUBE DEFECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRE-ECLAMPSIA; PREGNANCY; RIBOFLAVIN; VITAMIN B COMPLEX; VITAMIN B DEFICIENCY;

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTIHYPERTENSIVE AGENT; FOLIC ACID; HOMOCYSTEINE; RIBOFLAVIN; VITAMIN; VITAMIN B GROUP;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONCEPTION; CONFERENCE PAPER; DNA POLYMORPHISM; ENZYME ACTIVITY; FOLATE METABOLISM; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART DISEASE; HOMOZYGOSITY; HUMAN; HYPERTENSION; MATERNAL HYPERTENSION; META ANALYSIS (TOPIC); NEURAL TUBE DEFECT; OUTCOME ASSESSMENT; PREECLAMPSIA; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84893982447     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665113003613     Document Type: Article

References (106)

1. Klerk M, Verhoef P, Clarke R et al. (2002) MTHFR 677CT polymorphism and risk of coronary heart disease - a meta-analysis. JAMA 288, 2023-2031.
2. Holmes MV, Newcombe P, Hubacek JA et al. (2011) Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 378, 584-594.
3. Newton-Cheh C, Johnson T, Gateva V et al. (2009) Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 41, 666-676.
4. Czeizel A & Dudas I (1992) Prevention of the 1st occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 327, 1832-1835.
5. MRC Vitamin Study Research Group (1991) Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 338, 131-137.
6. Bodnar LM, Tang G, Ness RB et al. (2006) Periconceptional multivitamin use reduces the risk of preeclampsia. Am J Epidemiol 164, 470-477.
7. Hernandez-Diaz S, Werler MM, Louik C et al. (2002) Risk of gestational hypertension in relation to folic acid supplementation during pregnancy. Am J Epidemiol 156, 806-812.
8. Niu WQ, You YG & Qi Y (2012) Strong association of methylenetetrahydrofolate reductase gene C677T polymorphism with hypertension and hypertension-inpregnancy in Chinese: a meta-analysis. J Hum Hypertens 26, 259-267.
9. Botto LD & Yang QH (2000) 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 151, 862-877.
10. Frosst P, Blom HJ, Milos R et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10, 111-113.
11. Guenther BD, Sheppard CA, Tran P et al. (1999) The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol 6, 359-365.
12. Yamada K, Chen Z, Rozen R et al. (2001) Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci USA 98, 14853-14858.
13. Molloy AM, Daly S, Mills JL et al. (1997) Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 349, 1591-1593.
14. Jacques PF, Bostom AG, Williams RR et al. (1996) Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93, 7-9.
15. Brattstrom L, Wilcken DEL, Ohrvik J et al. (1998) Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease - the result of a meta-analysis. Circulation 98, 2520-2526.
16. Homocysteine Lowering Trialists' Collaboration (2005) Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 82, 806-812.
17. McNulty H, Dowey LRC, Strain JJ et al. (2006) Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C→T polymorphism. Circulation 113, 74-80.
18. Hustad S, Ueland P, Vollset S et al. (2000) Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 46, 1065-1071.
19. McNulty H, McKinley MC, Wilson B et al. (2002) Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. Am J Clin Nutr 76, 436-441.
20. Lewis SJ, Ebrahim S & Smith GD (2005) Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate' Br Med J 331, 1053-1056.
21. Wald DS, Law M & Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 325, 1202.
22. Casas JP, Bautista LE, Smeeth L et al. (2005) Homocysteine and stroke: evidence on a causal link from Mendelian randomisation. Lancet 365, 224-232.
23. Wald DS, Morris JK & Wald NJ (2011) Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis. Plos ONE 6, e16473.
24. Clarke R, Bennett DA, Parish S et al. (2012) Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. Plos Med 9, e1001177.
25. Kauwell GPA, Diaz ML, Yang Q et al. (2009) Folate: recommended intakes, consumption, and status. In Folate in Health and Disease, 2nd ed., pp. 467-490 [LB Bailey, editor]. Boca Raton, FL: Taylor & Francis.
26. Yang Q, Bailey L, Clarke R et al. (2012) Prospective study of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of all-cause and cardiovascular disease mortality among 6000 US adults. Am J Clin Nutr 95, 1245-1253.
27. Wang WY, Lee ET, Fabsitz RR et al. (2006) A longitudinal study of hypertension risk factors and their relation to cardiovascular disease - The Strong Heart Study. Hypertension 47, 403-409.
28. Lewington S, Clarke R, Qizilbash N et al. (2002) Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913.
29. Mongeau JG (1987) Heredity and blood-pressure in humans - an overview. Pediatr Nephrol 1, 69-75.
30. Levy D, DeStefano AL, Larson MG et al. (2000) Evidence for a gene influencing blood pressure on chromosome 17 - genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the Framingham Heart Study. Hypertension 36, 477-483.
31. Ehret GB, Munroe PB, Rice KM et al. (2011) Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478, 103-109.
32. Liu C, Li H, Qi Q et al. (2011) Common variants in or near FGF5, CYP17A1 and MTHFR genes are associated with blood pressure and hypertension in Chinese Hans. J Hypertens 29, 70-75.
33. Tomaszewski M, Debiec R, Braund PS et al. (2010) Genetic architecture of ambulatory blood pressure in the general population insights from cardiovascular genecentric array. Hypertension 56, 1069-U146.
34. Takeuchi F, Isono M, Katsuya T et al. (2010) Blood pressure and hypertension are associated with 7 Loci in the Japanese population. Circulation 121, 2302-U140.
35. Heux S, Morin F, Lea RA et al. (2004) The methylentetrahydrofolate reductase gene variant (C677T) as a risk factor for essential hypertension in Caucasians. Hypertens Res 27, 663-667.
36. Poduri A, Kumari S, Jain S et al. (2009) A case-control study of the association between the MTHFR gene and essential hypertension in Asian Indians. J Hum Hypertens 23, 140-142.
37. Inamoto N, Katsuya T, Kokubo Y et al. (2003) Association of methylenetetrahydrofolate reductase gene polymorphism with carotid atherosclerosis depending on smoking status in a Japanese general population. Stroke 34, 1628-1633.
38. Qian X, Lu Z, Tan M et al. (2007) A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur J Hum Genet 15, 1239-1245.
39. Koubaa N, Nakbi A, Smaoui A et al. (2007) Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: role of genetic and dietary factors. Clin Biochem 40, 1007-1014.
40. Benes P, Kankova K, Muzik J et al. (2001) Methylenetetrahydrofolate reductase polymorphism, type II diabetes mellitus, coronary artery disease, and essential hypertension in the Czech population. Mol Genet Metab 73, 188-195.
41. Koupepidou P, Deltas C, Christofides TC et al. (2005) The MTHFR 677TT and 677CT/1298AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure. Int Angiol 24, 287-294.
42. Jiang SQ, Hsu YH, Xu X et al. (2004) The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor. Thromb Res 113, 361-369.
43. Jiang S, Yu Y, Venners SA et al. (2011) Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. J Hum Hypertens 25, 172-177.
44. Xu H, Zheng H, Shen Y et al. (2012) Polymorphism of the methylenetetrahydrofolate reductase gene C677T and its 54 R. Reilly et al. influence on the antihypertensive and vascular protective effects of short-term lercanidipine treatment. Gene 500, 207-210.
45. Williams C, Kingwell BA, Burke K et al. (2005) Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype. Am J Clin Nutr 82, 26-31.
46. Markan S, Sachdeva M, Sehrawat BS et al. (2007) MTHFR 677 CT/MTHFR 1298 CC genotypes are associated with increased risk of hypertension in Indians. Mol Cell Biochem 302, 125-131.
47. Wilson CP, McNulty H, Scott JM et al. (2010) The MTHFR C677T polymorphism, B-vitamins and blood pressure. Proc Nutr Soc 69, 156-165.
48. McNulty H, Strain JJ, Pentieva K et al. (2012) Vitamins, infectious and chronic disease during adulthood and aging C1metabolism and CVD outcomes in older adults. Proc Nutr Soc 71, 213-221.
49. Horigan G, McNulty H, Ward M et al. (2010) Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C→T polymorphism in MTHFR. J Hypertens 28, 478-486.
50. Wilson CP, Ward M, McNulty H et al. (2012) Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up. Am J Clin Nutr 95, 766-772.
51. Wilson CP, McNulty H, Ward M et al. (2013) Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial. Hypertension 61, 1302-1308.
52. Antoniades C, Shirodaria C, Leeson P et al. (2009) MTHFR 677 C→T polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation 119, 2507-2515.
53. Daly L, Kirke P, Molloy A et al. (1995) Folate levels and neural-tube defects - implications for prevention. JAMA 274, 1698-1702.
54. Daly S, Mills JL, Molloy AM et al. (1997) Minimum effective dose of folic acid for food fortification to prevent neural-tube defects. Lancet 350, 1666-1669.
55. Pitkin RM (2007) Folate and neural tube defects. Am J Clin Nutr 85, 285S-288S.
56. Nilsen RM, Vollset SE, Gjessing HK et al. (2006) Patterns and predictors of folic acid supplement use among pregnant women: the Norwegian Mother and Child Cohort Study. Am J Clin Nutr 84, 1134-1141.
57. McNulty B, Pentieva K, Marshall B et al. (2011) Women's compliance with current folic acid recommendations and achievement of optimal vitamin status for preventing neural tube defects. Hum Reprod 26, 1530-1536.
58. Botto LD, Lisi A, Robert-Gnansia E et al. (2005) International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working' Br Med J 330, 571-573.
59. Centers for Disease Control and Prevention (2000) Folate Status in Women of Childbearing Age - United States, 1999. MMWR. Morbidity and Mortality Weekly Report 49: 962-5. http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm4942a4.htm
60. Honein MA, Paulozzi LJ, Mathews TJ et al. (2001) Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285, 2981-2986.
61. De Wals P, Tairou F, Van Allen MI et al. (2007) Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 357, 135-142.
62. Blencowe H, Cousens S, Modell B et al. (2010) Folic acid to reduce neonatal mortality from neural tube disorders. Int J Epidemiol 39, 110-121.
63. Friso S & Choi SW (2002) Gene-nutrient interactions and DNA methylation. J Nutr 132, 2382S-2387S.
64. Castro R, Rivera I, Ravasco P et al. (2004) 5,10- methylenetetrahydrofolate reductase (MTHFR) 677C→T and 1298A→C mutations are associated with DNA hypomethylation. J Med Genet 41, 454-458.
65. van der Put NMJ, Steegers Theunissen RPM, Frosst P et al. (1995) Mutated methylenetetrahydrofolate reductase as a risk factor for spina-bifida. Lancet 346, 1070-1071.
66. Blom HJ, Shaw GM, den Heijer M et al. (2006) Neural tube defects and folate: case far from closed. Nat Rev Neurosci 7, 724-731.
67. Ou CY, Stevenson R, Brown VK et al. (1995) C677T Homozygosity associated with thermolabile 5, 10 methylenetetrahydrofolate reductase as a risk factor for neural tube defects. Am J Hum Genet 57, A223-A223.
68. van der Put NMJ, van den Heuvel LP, Steegers Theunissen RPM et al. (1996) Decreased methylene tetrahydrofolate reductase activity due to the 677C→T mutation in families with spina bifida offspring. J Mol Med 74, 691-694.
69. van der Put NMJ, Eskes TKAB & Blom HJ (1997) Is the common 677C→T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects' A meta-analysis. QJM Mon J Assoc Physicians 90, 111-115.
70. Whitehead A, Gallagher P, Mills J et al. (1995) A geneticdefect in 5,10-methylenetetrahydrofolate reductase in neural-tube defects. QJM Mon J Assoc Physicians 88, 763-766.
71. van der Put NMJ, Trijbels FJM, Hol F et al. (1996) Mutated methylenetetrahydrofolate reductase in sporadic and hereditary spina bifida offspring. In Proceedings of III workshop on methionine metabolism, molecular mechanism and clinical implications, pp. 186-191 [JM Mato and A Caballero, editors]. Madrid: Consejo Superior de Investigaciones Cientificas.
72. Shields DC, Kirke PN, Mills JL et al. (1999) The 'thermolabile' variant of methylenetetrahydrofolate reductase and neural tube defects: an evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am J Hum Genet 64, 1045-1055.
73. Shaw GM, Rozen R, Finnell RH et al. (1998) Maternal vitamin use, genetic variation of infant methylenetetrahydrofolate reductase, and risk for spina bifida. Am J Epidemiol 148, 30-37.
74. Martinez de Villarreal LE, Delgado-Enciso I, Valdez- Leal R et al. (2001) Folate levels and N(5),N (10)-methylenetetrahydrofolate reductase genotype (MTHFR) in mothers of offspring with neural tube defects: a case-control study. Arch Med Res 32, 277-282.
75. Volcik KA, Blanton SH, Tyerman GH et al. (2000) Methylenetetrahydrofolate reductase and spina bifida: evaluation of level of defect and maternal genotypic risk in Hispanics. Am J Med Genet 95, 21-27.
76. Christensen B, Arbour L, Tran P et al. (1999) Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 84, 151-157.
77. Reilly R, Ward M, McNulty H et al. (2012) MTHFR 677 TT genotype and folate requirements for preventing neural tube defects: is there a case for personalised nutrition' Proc Nutr Soc 71, E29.
78. Crider KS, Zhu J, Hao L et al. (2011) MTHFR 677C→T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation. Am J Clin Nutr 93, 1365-1372.
79. Also-Rallo E, Lopez-Quesada E, Urreizti R et al. (2005) Polymorphisms of genes involved in homocysteine metabolism in preeclampsia and in uncomplicated pregnancies. Eur J Obstet Gynecol Reprod Biol 120, 45-52.
80. Saudan P, Brown MA, Buddle ML et al. (1998) Does gestational hypertension become pre-eclampsia' Br J Obstet Gynaecol 105, 1177-1184.
81. Hibbard BM (1964) The role of folic acid in pregnancy; with particular reference to anaemia, abruption and abortion. J Obstet Gynaecol Br Commonw 71, 529-542.
82. Hibbard BM, Hibbard ED & Jeffcoate TN (1965) Folic acid and reproduction. Acta Obstet Gynecol Scand 44, 375-400.
83. Stone ML, Luhby AL, Feldman R et al. (1967) Folic acid metabolism in pregnancy. Obstet Gynecol 99, 638-648.
84. Stone ML (1968) Effects on the fetus of folic acid deficiency in pregnancy. Clin Obstet Gynecol 11, 1143-1153.
85. Ray JG & Mamdani MM (2002) Association between folic acid food fortification and hypertension or preeclampsia in pregnancy. Arch Intern Med 162, 1776-1777.
86. Hernandez-Diaz S, Wu XF, Hayes C et al. (2005) Methylenetetrahydrofolate reductase polymorphisms and the risk of gestational hypertension. Epidemiology 16, 628-634.
87. Sohda S, Arinami T, Hamada H et al. (1997) Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 34, 525-526.
88. Grandone E, Margaglione M, Colaizzo D et al. (1997) Factor V Leiden, C→T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 77, 1052-1054.
89. Wilcken B, Bamforth F, Li Z et al. (2003) Geographical and ethnic variation of the 677C→T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas worldwide. J Med Genet 40, 619-625.
90. Villar J, Say L, Shennan A et al. (2004) Methodological and technical issues related to the diagnosis, screening, prevention, and treatment of pre-eclampsia and eclampsia. Int J Gynaecol Obstet 85, S28-S41.
91. Perez-Mutul J, Gonzalez-Herrera L, Sosa-Cabrera T et al. (2004) A mutation in the 5,10-methylenetetrahydrofolate reductase gene is not associated with preeclampsia in women of southeast Mexico. Arch Med Res 35, 231-234.
92. Davalos IP, Moran MC, Martinez-Abundis E et al. (2005) Methylenetetrahydrofolate reductase C677T polymorphism and factor V Leiden variant in Mexican women with preeclampsia/eclampsia. Blood Cells Mol Dis 35, 66-69.
93. Canto MJ, Buixeda M, Palau J et al. (2007) Early ultrasonographic diagnosis of diastrophic dysplasia at 12 weeks of gestation in a fetus without previous family history. Prenat Diagn 27, 976-978.
94. Kosmas IP, Tatsioni A & Ioannidis JPA (2004) Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 22, 1655-1662.
95. Xia X, Chang W & Cao Y (2012) Meta-analysis of the methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to pre-eclampsia. Hypertens Res 35, 1129-1134.
96. Kupferminc MJ (2005) Thrombophilia and pregnancy. Curr Pharm Des 11, 733-746.
97. Powers RW, Minich LA, Lykins DL et al. (1999) Methylenetetrahydrofolate reductase polymorphism, folate, and susceptibility to preeclampsia. J Soc Gynecol Invest 6, 74-79.
98. Kobashi G, Yamada H, Asano T et al. (2000) Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and preeclampsia in Japanese women. Am J Med Genet 93, 122-125.
99. Laivuori H, Kaaja R, Ylikorkala O et al. (2000) 677 C→T polymorphism of the methylenetetrahydrofolate reductase gene and preeclampsia. Obstet Gynecol 96, 277-280.
100. Rigo J, Nagy B, Fintor L et al. (2000) Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of Factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. Hypertens Pregnancy 19, 163-172.
101. Morrison ER, Miedzybrodzka ZH, Campbell DM et al. (2002) Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 87, 779-785.
102. Prasmusinto D, Skrablin S, Hofstaetter C et al. (2002) The methylenetetrahydrofolate reductase 677 C→T polymorphism and preeclampsia in two populations. Obstet Gynecol 99, 1085-1092.
103. Pegoraro RJ, Chikosi A, Rom L et al. (2004) Methylenetetrahydrofolate reductase gene polymorphisms in black South Africans and the association with preeclampsia. Acta Obstet Gynecol Scand 83, 449-454.
104. Williams MA, Sanchez SE, Zhang C et al. (2004) Methylenetetrahydrofolate reductase 677C→T polymorphism and plasma folate in relation to pre-eclampsia risk among Peruvian women. J Matern Fetal Neonatal Med 15, 337-44.
105. Yilmaz H, Unlucerci Y, Gurdol F et al. (2004) Association of pre-eclampsia with hyperhomocysteinaemia and methylenetetrahydrofolate reductase gene C677T polymorphism in a Turkish population. Aust N Z J Obstet Gynaecol 44, 423-427.
106. Stiefel P, Luisa Miranda M, Bellido LM et al. (2009) Genotype of the CYBA promoter-930A/G, polymorphism C677T of the MTHFR and APOE genotype in patients with hypertensive disorders of pregnancy: an observational study. Med Clin 133, 657-661.